• Japanese
  • Korean
  • Chinese
Cover Image

Global Ovarian Cancer Drugs Market 2011-2015

Abstract

TechNavio's analysts forecast the Global Ovarian Cancer Drugs market to grow at a CAGR of 13.1 percent over the period 2011-2015. One of the key factors contributing to this market growth is the increasing prevalence of ovarian cancer. The Global Ovarian Cancer Drugs market has also been witnessing the trend of the use of combination therapies for the treatment of ovarian cancer. However, patent expiration of key drugs could pose a challenge to the growth of this market.

TechNavio's report, the Global Ovarian Cancer Drugs Market 2011-2015, has been prepared based on an in-depth analysis of the market with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors dominating this market space include Eli Lilly and Co., GlaxoSmithKline plc, Bristol Myers Squibb Co., and Roche Pharmaceuticals.

Other vendors mentioned in the report are Johnson & Johnson, Amgen Inc., Eisai Co. Ltd., BioNumerik Pharmaceuticals Inc., Endocyte Inc., Oasmia Pharmaceutical AB, Boehringer Ingelheim GmbH, and AstraZeneca plc.

Key questions answered in this report:

  • What will the market size be in 2015 and at what rate will it grow?
  • What key trends is this market subject to?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the opportunities and threats faced by each of these key vendors?
  • What are the strengths and weaknesses of each of these key vendors?

You can request one free hour of analyst time when you purchase this report. Details provided within the report.

Table of Contents

01. Executive Summary

02. Introduction

03. Market Coverage

  • Market Overview
  • Product Offerings

04. Market Landscape

  • Market Size
  • Five Forces Analysis

05. Geographical Segmentation

06. Key Leading Countries

  • USA
  • Germany
  • UK
  • Economic Indicators of Key Leading Countries

07. Rate of Incidence and Prevalence

08. Vendor Landscape

  • Major Vendors of the Global Cancer Drugs market

09. Buying Criteria

10. Market Growth Drivers

11. Drivers and their Impact

12. Market Challenges

13. Impact of Drivers and Challenges

14. Market Trends

15. Key Vendor Analysis

  • 15.1. Eli Lilly and Co.
    • Business Overview
    • SWOT Analysis
  • 15.2. GlaxoSmithKline plc
    • Business Overview
    • SWOT Analysis
  • 15.3. Bristol-Myers Squibb Co.
    • Business Overview
    • SWOT Analysis
  • 15.4. Roche Pharmaceuticals
    • Business Overview
    • SWOT Analysis

16. Other Reports in this Series

List of Exhibits:

  • Exhibit 1: Global Ovarian Cancer Drugs Market 2011-2015 (US$ million)
  • Exhibit 2: Global Ovarian Cancer Drugs Market by Geographical Segmentation 2011
  • Exhibit 3: Global Cancer Drugs Market by Vendor Segmentation 2011
Show More
Pricing
Get Notified
Email me when related reports are published